patent_id,patent_date,patent_title,patent_num_times_cited_by_us_patents,cpc_subclass_ids
12421512,2025-09-23,CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation,0,A61K|C12N|G01N|G16B
12421317,2025-09-23,Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies,0,A61K|A61P|C07K
12421315,2025-09-23,CLL-1 targeted immunotherapies,0,A61K|A61P|C07K|C12N
12419963,2025-09-23,Diels-Alder conjugation methods,0,A61K|A61P
12419282,2025-09-23,Non-human animals expressing humanized CD3 complex,0,A01K|C07K|C12N|G01N|Y02A
12415856,2025-09-16,EGFR x CD28 multispecific antibodies,0,A61K|A61P|C07K|C12N
12414551,2025-09-16,Genetically modified major histocompatibility complex mice,0,A01K|C07K|C12N
12411141,2025-09-09,LC-MS methods for antibody isotyping and quantification,0,G01N|H01J
12410442,2025-09-09,Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems,0,A01K|A61K|A61P|C07K|C12N|C12Y
12404505,2025-09-02,Delivery of a gene-editing system with a single retroviral particle and methods of generation and use,0,A61K|C07K|C12N|C12Y
12402611,2025-09-02,Genetically modified mice and engraftment,0,A01K|A61K|C07K|C12N|Y02A
12399182,2025-08-26,Quantitation and identification of dimers in co-formulations,0,G01N
12398434,2025-08-26,Compositions and methods for detecting a biological contaminant,0,C12Q
12398212,2025-08-26,Methods for treating or preventing asthma by administering an IL-4R antagonist,0,A61K|A61P|C07K|Y02A
12398176,2025-08-26,Use of Raman spectroscopy in downstream purification,0,C07K|G01N
12397028,2025-08-26,Adoptive cellular therapy,0,A61K|A61P|C07K|C12N|Y02A
12396952,2025-08-26,Tuning of release kinetics in hydrogels,0,A61K|C07K
12396444,2025-08-26,Mouse comprising a humanized TRKB locus,0,A01K|A61K|C07K|C12N|C12Y
12391920,2025-08-19,Models of tauopathy,0,A01K|A61K|C12N
12391753,2025-08-19,Antigen binding molecule formats,0,A61K|A61P|C07K
12391734,2025-08-19,"PD-1 homing endonuclease variants, compositions, and methods of use",0,A61K|A61P|C07K|C12N|C12Y
12389889,2025-08-19,Mouse having a humanized cluster of differentiation 47 gene,0,A01K|A61P|C07K|C12N|G01N
12389888,2025-08-19,Mice expressing a limited immunoglobulin light chain repertoire,0,A01K|C07K|C12N
12378557,2025-08-05,Treatment of sepsis with PCSK9 and LDLR modulators,0,A61P|C12N|C12Q
12378258,2025-08-05,"Biologically active molecules, conjugates thereof, and therapeutic uses",0,A61K|A61P|C07D
12377159,2025-08-05,Steroids and protein-conjugates thereof,0,A61K|A61P|C07J
12376573,2025-08-05,Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire,0,A01K|C07K|C12N
12372502,2025-07-29,Methods for chromatography resin slurry determination,0,B01D|G01F|G01N
12371503,2025-07-29,Methods of treatment using a leptin receptor agonist antibody,0,A61K|A61P|C07K
12371487,2025-07-29,Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same,0,C07K|G01N
12371475,2025-07-29,Nucleic acids encoding anchor modified antibodies and uses thereof,0,A01K|C07K|C12N|Y02A
12370257,2025-07-29,Materials and methods of treating MHC-I-opathy risk haplotypes,0,A61K|C07K|C12N|C12Q
12369570,2025-07-29,Humanized IL-15 animals,0,A01K|C07K|C12N
12365711,2025-07-22,TGFβ signal convertor,0,A61K|A61P|C07K
12359201,2025-07-15,17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof,0,C12N
12359166,2025-07-15,Taurine supplemented cell culture medium and methods of use,0,C12N
12359165,2025-07-15,Taurine supplemented cell culture medium and methods of use,0,C12N
12356967,2025-07-15,Immunoglobulin lambda light chain and uses thereof,0,A01K|C07K|C12N
12350374,2025-07-08,Fabrication of protein-encapsulating microgels,0,A61K|A61P|C07K
12350318,2025-07-08,Combination therapy to treat brain cancer,0,A61K|A61N|A61P|C07K|C12Q
12344677,2025-07-01,"Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof",0,A61K|A61P|C07K
12344665,2025-07-01,Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody,0,A61K|A61P|C07K
12344654,2025-07-01,Mage A4 T cell receptors,0,A61K|A61P|C07K|C12N
12342801,2025-07-01,Methods for producing antigen-binding proteins against foreign antigens,0,A01K|C07K|C12N|C12Y
12338274,2025-06-24,Anti-VEGF protein compositions and methods for producing the same,0,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12338199,2025-06-24,Bis-octahydrophenanthrene carboxamides and protein conjugates thereof,0,A61K|A61P|C07C
12337199,2025-06-24,Stable antibody formulation,0,A61K|A61P|C07K
12331341,2025-06-17,Serum-free cell culture medium,0,C07K|C12N|C12P
12331127,2025-06-17,Therapeutic uses of anti-GITR antibodies,0,A61K|A61P|C07K
12331109,2025-06-17,Antigen binding molecule formats,0,A61K|A61P|C07K
12331099,2025-06-17,VEGF antagonist formulations suitable for intravitreal administration,0,A61K|A61M|A61P|C07K
12325752,2025-06-10,Immunoglobulin proteins that bind to NPR1 agonists,0,A61K|A61P|C07K
12320814,2025-06-03,Characterization of adeno-associated virus using microchip capillary electrophoresis,0,G01N
12320790,2025-06-03,Method and system of identifying and quantifying antibody fragmentation,0,G01N
12319728,2025-06-03,Anti-VEGF protein compositions and methods for producing the same,0,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12319724,2025-06-03,IL2 agonists and methods of use thereof,0,A61K|A61P|C07K|C12N
12317874,2025-06-03,Method of using a genetically modified mouse that expresses human albumin,0,A01K|A61K|C07K|C12N
12313589,2025-05-27,Liquid chromatography-mass spectrometry (LC-MS) methods for analyzing ampholyte lot variation,0,G01N|G16C
12310340,2025-05-27,Humanized IL-4 and IL-4Rα animals,0,A01K|C07K
12304969,2025-05-20,Factor XI A2 domain-binding antibodies and methods of use thereof,0,A61K|A61P|C07K
12297465,2025-05-13,"CBLB endonuclease variants, compositions, and methods of use",0,A61K|C07K|C12N
12297451,2025-05-13,Cell culture medium,0,C12N
12297279,2025-05-13,Compositions and methods for treating pain in subjects with rheumatoid arthritis,0,A61K|A61P|C07K
12297257,2025-05-13,Multispecific antigen-binding molecules and uses thereof,0,A61K|A61P|C07K|C12N
12297207,2025-05-13,"Maytansinoid derivatives, conjugates thereof, and methods of use",0,A61K|A61P|C07D
12295354,2025-05-13,Non-human animals expressing exogenous terminal deoxynucleotidyltransferase,0,A01K|C07K|C12N|C12Y
12291571,2025-05-06,Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody,0,A61K|A61P|C07K
12291563,2025-05-06,Metabolically optimized cell culture,0,C07H|C07K|C12N|C12P|C12Q
12291560,2025-05-06,Dimerizing agent regulated immunoreceptor complexes,0,A61K|A61P|C07K|C12N|C12Y
12291559,2025-05-06,Compositions and methods for treating cancer,0,A61K|A61P|C07K|C12N
12286677,2025-04-29,Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation,0,C12Q
12282004,2025-04-22,Universal modular properties test fixture,0,G01N
12281173,2025-04-22,Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor,0,A61K|A61P|C07K
12280124,2025-04-22,Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof,0,A61K|A61P
12280093,2025-04-22,Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy,0,A61K|A61P
12275792,2025-04-15,Antigen-binding proteins that activate the leptin receptor,0,A61K|A61P|C07K
12274747,2025-04-15,Compositions and methods for treating cytokine release syndrome,0,A61K|A61P|C07K
12269897,2025-04-08,Anti-PCSK9 antibodies,0,A61K|A61P|C07K|C12N|C12Y|G01N|Y10S
12269889,2025-04-08,Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels,0,A61K|A61P|C07K|C12N
12268730,2025-04-08,Use of a VEGF antagonist to treat angiogenic eye disorders,0,A61K|A61P|C07K
12264366,2025-04-01,Genome-based methods for reducing cardiovascular risk,0,A61K|C07K|C12Q|G16B
12264343,2025-04-01,TCRa homing endonuclease variants,0,A61K|C12N
12259373,2025-03-25,High confidence compound identification by liquid chromatography-mass spectrometry,0,G01N|H01J
12259355,2025-03-25,Microchip capillary electrophoresis assays and reagents,0,G01N
12258627,2025-03-25,Kelch domain containing 7B (KLHDC7B) variants and uses thereof,0,A61K|C12Q|G01N
12258597,2025-03-25,Methods and compositions for therapeutic protein delivery,0,A01K|A61K|A61P|C07K|C12N|C12Y
12258412,2025-03-25,Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies,0,A61K|A61P|C07K
12256720,2025-03-25,Humanized dipeptidyl-peptidase IV (DPP4) animals,0,A01K|A61P|C12N|C12Q|C12Y|G01N
12253490,2025-03-18,Microchip capillary electrophoresis assays and reagents,0,G01N
12252544,2025-03-18,"Anti-CD63 antibodies, conjugates, and uses thereof",0,A61K|A61P|C07K|C12N
12252530,2025-03-18,Human antibodies to Fel d1 and methods of use thereof,0,A61K|A61P|C07K|C12N
12252520,2025-03-18,Myosin 15 promoters and uses thereof,0,A61K|C07K|C12N
12251440,2025-03-18,Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments,0,A61K|A61P|C07K|Y02A
12250931,2025-03-18,Genetically modified mouse with a humanized PNPLA3 gene and methods of use,0,A01K|A61K|C12N
12247983,2025-03-11,Protein A chromatography-electrospray ionization mass spectrometer,0,G01N|H01J
12246305,2025-03-11,Systems and methods for chromatography use and regeneration,0,B01D|B01J|C07K|G01N
12240908,2025-03-04,N-terminal scFv multispecific binding molecules,0,A61K|A61P|C07K
12240907,2025-03-04,N-terminal scFv multispecific binding molecules,0,A61K|A61P|C07K
12240891,2025-03-04,Online chromatography and electrospray ionization mass spectrometer,0,B01D|C07K|G01N|H01J
12239687,2025-03-04,Sustained release formulations using non-aqueous membrane emulsification,0,A61K|C07K
12239111,2025-03-04,Humanized IL-6 and IL-6 receptor,0,A01K|C07K|C12N
12234472,2025-02-25,Eukaryotic cells comprising adenovirus-associated virus polynucleotides,0,C07K|C12N
12234460,2025-02-25,Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors,0,A61K|C07K|C12N|C12Q
12234277,2025-02-25,Hydrophobic interaction chromatography for viral clearance,0,A61K|C07K|C12Q|G01N
12230364,2025-02-18,Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden,0,A61P|C12Q|G16B|Y02A
12227740,2025-02-18,"CBLB endonuclease variants, compositions, and methods of use",0,A61K|A61P|C07K|C12N|C12Y
12221619,2025-02-11,Taurine supplemented cell culture medium and methods of use,0,C12N
12216122,2025-02-04,"Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)",0,C07K|C12N|C12Q|C12Y|G01N
12215322,2025-02-04,Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors,0,A61K|A61P|C12N|C12Q
12215148,2025-02-04,Antigen binding molecule formats,1,A61K|A61P|C07K
12215138,2025-02-04,Compositions and methods for internalizing enzymes,0,A61K|A61P|C07K|C12N
12215131,2025-02-04,IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof,0,A61K|A61P|C07K|C12N
12214023,2025-02-04,Compositions and methods for expressing factor IX,0,A61K|A61P|C12N|C12Y
12209238,2025-01-28,CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation,1,A61K|C12N|G01N|G16B
12209180,2025-01-28,Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists,0,A61K|A61P|C07C|C07D|C07H|C08B|C08L
12207628,2025-01-28,ADAM6 mice,0,A01K|B60H|C07K|C12N
12202883,2025-01-21,Anti-VEGF protein compositions and methods for producing the same,0,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12201673,2025-01-21,Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein,0,A61K|A61P
12201096,2025-01-21,Non-human animals comprising a humanized coagulation factor 12 locus,0,A01K|C07K|C12N|C12Q
12196761,2025-01-14,Use of LC-MS/MS to quantitate protein biomarkers,0,C12Q|G01N|G16B|G16H
12187792,2025-01-07,IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer,0,A61K|A61P|C07K
12187772,2025-01-07,IL10 agonists and methods of use thereof,0,A61K|A61P|C07K
12186378,2025-01-07,Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists,0,A61K|A61P|C12N|C12Q
12180272,2024-12-31,Antigen binding molecule formats,1,A61K|A61P|C07K
12174199,2024-12-24,System and method of analysis of a protein using liquid chromatography-mass spectrometry,0,G01N|H01J
12174173,2024-12-24,System and method for characterizing protein dimerization,0,C07K|C12N|G01N
12172106,2024-12-24,Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor,0,B01D|G01N
12169204,2024-12-17,Coupled native mass spectrometry for antibody analysis,0,B01D|G01N|H01J
12169203,2024-12-17,Native microfluidic CE-MS analysis of antibody charge heterogeneity,0,G01N
12169199,2024-12-17,Activity based host cell protein profiling,0,A61K|C12Y|G01N
12168681,2024-12-17,Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof,0,A61K|A61P|C07K
12168036,2024-12-17,Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins,0,A61K|A61P|C07K
12163192,2024-12-10,Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof,0,A61K|A61P|C12N|C12Q
12163122,2024-12-10,Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants,0,C12N|C12P
12162943,2024-12-10,High affinity human antibodies to human IL-4 receptor,0,A61K|A61P|C07K
12161097,2024-12-10,Non-human animals having a humanized signal-regulatory protein gene,0,A01K|A61K|C07K|C12N|C12Y|G01N
12158474,2024-12-03,Method of characterization of visible and/or sub-visible particles in biologics,0,C07K|G01N|H01J
12158473,2024-12-03,Multimeric protein purity determination,0,C07K|G01N
12157916,2024-12-03,Mitochondrial DNA quality control,0,C12Q|G16B
12157891,2024-12-03,Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors,0,A61P|C12N|C12Q|G01N
12157758,2024-12-03,Readily isolated bispecific antibodies with native immunoglobulin format,0,A61K|C07K
12157756,2024-12-03,Detection and quantification of glycosylated peptides,0,B01D|C07K|G01N
12153053,2024-11-26,Unbiased and high-throughput identification and quantification of host cell protein impurities by automated iterative LC-MS/MS (HCP-AIMS) for therapeutic protein development,0,G01N|H01J
12152067,2024-11-26,Human antibodies to ebola virus glycoprotein,0,A61K|A61P|C07K
12152056,2024-11-26,Method and chromatography system for determining amount and purity of a multimeric protein,0,B01D|C07K|G01N
12150959,2024-11-26,Chimeric antigen receptors with BCMA specificity and uses thereof,0,A61K|A61P|C07K|C12N
12144864,2024-11-19,Tubulysins and protein-tubulysin conjugates,0,A61K|A61P|C07K
12139546,2024-11-12,Methods of treating urea cycle disorders by interfering with glucagon receptor signaling,0,A61K|A61P|C07K
12135328,2024-11-05,Tandem mass tag multiplexed quantitation of post-translational modifications of proteins,0,G01N
12135327,2024-11-05,Systems and methods for identifying HLA-associated tumor peptides,0,C07K|C40B|G01N
12134631,2024-11-05,Hydrophilic linkers for antibody drug conjugates,0,A61K|A61P|C07J
12127537,2024-10-29,Genetically modified non-human animals and methods of use thereof,0,A01K|C07K|C12N
12127536,2024-10-29,Humanized M-CSF mice,0,A01K|A61K|C07K|C12N|G01N
12123879,2024-10-22,Heavy peptide approach to accurately measure unprocessed C-terminal lysine,0,G01N
12123001,2024-10-22,Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors,0,A61K|A61P|C12N|C12Q|C12Y
12117452,2024-10-15,Identification of host cell proteins,0,G01N
12116622,2024-10-15,Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF,0,A61K|A61P|C07K|C12Q|G16B|G16H
12115216,2024-10-15,Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof,0,A61K|A61P|C07K
12110502,2024-10-08,Models of tauopathy,1,A01K|A61K|C12N
12103960,2024-10-01,VEGF traps and mini-traps and methods for treating ocular disorders and cancer,0,A61K|A61P|C07K
12099042,2024-09-24,Use of liquid chromatography and mass spectrometry to characterize oligonucleotides,0,C12Q|G01N|H01J
12096754,2024-09-24,Non-human animals having a humanized lymphocyte-activation gene 3,0,A01K|A61K|C07H|C07K|C12N
12091460,2024-09-17,Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation,0,A61B|A61K|C07K
12091449,2024-09-17,Anti-PfRH5 antibodies and antigen-binding fragments thereof,0,A61K|A61P|C07K|Y02A
12091440,2024-09-17,IL2 and peptide-MHC complex fusion proteins and methods of use thereof,0,A61K|A61P|C07K|C12N
12090201,2024-09-17,Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody,1,A61K|A61P|C07K
12090193,2024-09-17,Glucagon-like peptide 1 receptor agonists and uses thereof,0,A61K|A61P|C07K|C12N
12089576,2024-09-17,Nucleic acids comprising a modified rodent activin a receptor type 1 (Acvr1) gene,0,A01K|C12N
12089575,2024-09-17,Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins,0,A01K|A61K|A61P|C07K
12084516,2024-09-10,Anti-C5 antibody combinations and uses thereof,0,A61K|A61P|C07K
12083141,2024-09-10,Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors,0,A61K|C07K|C12N|C12Q|G01N
12082566,2024-09-10,Rodent animals expressing human CR1,0,A01K|A61K|C07K|C12N
12082565,2024-09-10,Non-human animals models of retinoschisis,0,A01K|A61P|C07K|C12N|G01N
12077782,2024-09-03,Viral clearance by low pH hold,0,A61K|C07K|C12N
12077603,2024-09-03,Multispecific antigen-binding molecules for cell targeting and uses thereof,0,C07K
12077593,2024-09-03,Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies,0,A61J|A61K|A61P|C07K
12077587,2024-09-03,Anti-CD8 antibodies and uses thereof,0,A61K|C07K|G01N
12077570,2024-09-03,Anti-VEGF protein compositions and methods for producing the same,0,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12071669,2024-08-27,Methods and systems for detection of abnormal karyotypes,0,C12Q|G16B
12070506,2024-08-27,Steroids and antibody-conjugates thereof,1,A61K|C07J|C07K
12070502,2024-08-27,Process for reducing subvisible particles in a pharmaceutical formulation,0,A61K
12070460,2024-08-27,Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors,0,A61K|A61P|C07K|C12N|C12Q|C12Y
12068729,2024-08-20,Anti-factor XII/XIIa antibodies and uses thereof,0,A61P|C07K|H03F
12066246,2024-08-20,Target residual moisture content for lyophilized drug product,0,A61K|F26B
12065661,2024-08-20,Genetic modification of rats,0,A01K|A61D|C12N
12065508,2024-08-20,Multispecific antigen-binding molecules for cell targeting and uses thereof,0,C07K
12065506,2024-08-20,Anti-TMPRSS2 antibodies and antigen-binding fragments,0,A61K|A61P|C07K|C12N
12063915,2024-08-20,Humanized T cell co-receptor mice,0,A01K|C07K|C12N
12060571,2024-08-13,Methods and compositions for modifying a targeted locus,0,A01K|C07K|C12N
12060428,2024-08-13,Anti-IL36R antibodies,0,A61K|A61P|C07K
12060419,2024-08-13,CD79A chimeric antigen receptors,0,A61K|C07K|C12N
12058987,2024-08-13,Mouse having a humanized B-cell activating factor gene,0,A01K|C07K|C12N|G01N
12055551,2024-08-06,Methods for mitigating drug target interference in an anti-drug antibody (ADA) immunoassay,0,G01N
12055518,2024-08-06,Liquid chromatography-mass spectrometry (LC-MS) methods for analyzing ampholyte lot variation,1,G01N|G16C
12054751,2024-08-06,Fucosylation-deficient cells,0,C07K|C12N|C12P|C12Y|Y02P
12054557,2024-08-06,Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer,0,A61K|A61P|C07K
12054533,2024-08-06,Anti-VEGF protein compositions and methods for producing the same,0,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12054532,2024-08-06,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12053534,2024-08-06,Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging,0,A61K|A61P|C07K
12049670,2024-07-30,Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof,0,A61K|A61P|C12Q
12049489,2024-07-30,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12042538,2024-07-23,Methods of reducing particle formation and compositions formed thereby,0,A61K|C07K
12041918,2024-07-23,Production of fertile XY female animals by silencing of genes on the Y chromosome,0,A01K|C12N|C12Q|G01N
12037596,2024-07-16,Targeted modification of rat genome,0,A01K|A61D|C07K|C12N
12037411,2024-07-16,"Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof",0,A61K|A61P|C07K
12037401,2024-07-16,Anti-TrkB monoclonal antibodies and methods of use,0,A61K|A61P|C07K
12037388,2024-07-16,Anti-IL-33 antibodies and uses thereof,0,A61K|A61P|C07K
12036288,2024-07-16,Methods of using humanized FCγR mice to assay Fc regions,0,A01K|A61K|C07K|G01N
12036280,2024-07-16,High concentration protein formulation,0,A61K
12036256,2024-07-16,Adoptive cellular therapy,1,A61K|A61P|C07K|C12N|Y02A
12031151,2024-07-09,Methods of improving protein titer in cell culture,0,C12N
12030935,2024-07-09,Anti-PDGF-B antibodies and pharmaceutical composition thereof,0,A61K|A61P|C07K
12029788,2024-07-09,Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody,0,A61K|A61P|C07K
12025599,2024-07-02,Systems and methods for failure mode detection in process chromatography,0,B01D|C07K|G01N
12024570,2024-07-02,Anti-CTLA-4 antibodies and uses thereof,0,A61K|A61P|C07K|C12N
12024556,2024-07-02,Anti-Staphylococcus antibodies and uses thereof,0,A61K|A61P|C07K
12018259,2024-06-25,Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors,0,A61K|A61P|C12N|C12Q
12012445,2024-06-18,Anti-VEGF protein compositions and methods for producing the same,2,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12012444,2024-06-18,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
12010979,2024-06-18,Non-human animals comprising a humanized TTR locus and methods of use,0,A01K|A61K|C07K|C12N
12007396,2024-06-11,Methods for characterizing low-abundance host cell proteins,0,G01N
12000840,2024-06-04,Methods for de novo protein sequencing,0,C07K|G01N|G16B|H01J
12000839,2024-06-04,Methods for characterizing disulfide bonds,0,A61K|G01N
12000811,2024-06-04,Method and system of identifying and quantifying antibody fragmentation,1,G01N
11999799,2024-06-04,Anti-TMPRSS2 antibodies and antigen-binding fragments,0,A61K|A61P|C07K|C12N
11999777,2024-06-04,Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies,1,A61K|A61P|C07K
11988668,2024-05-21,Concentration-dependent self-interaction assay,0,G01N
11986511,2024-05-21,Use of a VEGF antagonist to treat angiogenic eye disorders,1,A61K|A61P|C07K
11981913,2024-05-14,Methods for analysis of viral capsid protein composition,0,C07K|C12N|G01N
11977081,2024-05-07,ANGPTL8 assay and uses thereof,0,G01N
11975045,2024-05-07,Use of a VEGF antagonist to treat angiogenic eye disorders,1,A61K|A61P|C07K
11971393,2024-04-30,Devices and systems for chromatography column bed support management and related methods,0,B01D|G01N
11970724,2024-04-30,Serum-free cell culture medium,0,C07K|C12N|C12P
11965161,2024-04-23,Methods and compositions for sensitization of tumor cells to immune therapy,0,A61K|C12N
11965020,2024-04-23,Antigen binding molecule formats,0,A61K|A61P|C07K
11964016,2024-04-23,Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy,0,A61K|A61P|C07K
11963521,2024-04-23,Humanized IL-4 and IL-4Rα animals,0,A01K|C07K
11959897,2024-04-16,High confidence compound identification by liquid chromatography-mass spectrometry,1,G01N|H01J
11958910,2024-04-16,"Bispecific antigen binding molecules that bind HER2, and methods of use thereof",0,A61K|A61P|C07K
11958894,2024-04-16,Anti-VEGF protein compositions and methods for producing the same,3,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11957704,2024-04-16,Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors,1,A61K|A61P|C12Q
11957687,2024-04-16,Modulators of HSD17B13 and methods of use thereof,0,A61K|A61P|C07D
11952430,2024-04-09,Multispecific antigen-binding molecules for cell targeting and uses thereof,0,C07K
11951216,2024-04-09,Polymer protein microparticles,0,A61K|A61P
11950578,2024-04-09,ADAM6 mice,1,A01K|B60H|C07K|C12N
11945872,2024-04-02,Anti-ACVR1 antibodies and uses thereof,0,A61K|A61P|C07K
11944666,2024-04-02,Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein,0,A61K|A61P
11939635,2024-03-26,Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR),1,C12Q
11937587,2024-03-26,Non-human animals expressing humanized CD3 complex,0,A01K|C07K|C12N|G01N|Y02A
11932859,2024-03-19,Nuclease-mediated DNA assembly,0,C12N
11932692,2024-03-19,Methods of treating cancer pain by administering a PD-1 inhibitor,0,A61K|A61P|C07K
11932684,2024-03-19,Online chromatography and electrospray ionization mass spectrometer,1,B01D|C07K|G01N|H01J
11926670,2024-03-12,Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies,0,A61K|A61M|A61P|C07K
11926668,2024-03-12,Anti-PD-1 antibodies for treatment of lung cancer,1,A61K|A61P|C07K
11926661,2024-03-12,Human antibodies to artemin and methods of use thereof,0,A61K|A61P|C07K
11919972,2024-03-05,Peptide libraries with non-canonical amino acids,0,A61K|C07K|C12N|C40B|G01N
11919965,2024-03-05,Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies,0,A61K|A61P|C07K
11912767,2024-02-27,EGFR × CD28 multispecific antibodies,1,A61K|A61P|C07K|C12N
11910788,2024-02-27,Mouse having a humanized cluster of differentiation 47 gene,0,A01K|A61P|C07K|C12N|G01N
11910787,2024-02-27,Rodents having a humanized TMPRSS gene,0,A01K|A61K|C07K|C12N
11905332,2024-02-20,"Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof",0,A61K|A61P|C07K
11904017,2024-02-20,Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab,1,A61K|A61M|A61P|C07K
11899023,2024-02-13,Quantitation and identification of dimers in co-formulations,1,G01N
11897945,2024-02-13,Methods of treating allergy using anti-Bet v 1 antibodies,0,A61K|A61P|C07K
11896682,2024-02-13,Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof,0,A61K|A61P|C07K|G01N
11891618,2024-02-06,Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use,0,A01K|C07K|C12N
11891607,2024-02-06,Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors,0,A61K|C07K|C12N|C12Q
11885811,2024-01-30,Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis,0,B01D|G01N|H01J
11885779,2024-01-30,Ultraviolet monitoring of chromatography performance by orthogonal partial least squares,0,G01N|G06F
11884736,2024-01-30,Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R),2,A61K|A61P|C07K
11884707,2024-01-30,"Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same",0,A61K|C07K|G01N
11884698,2024-01-30,Systems and methods for preparing a polypeptide from a mixture,0,B01D|C07K
11879896,2024-01-23,Therapeutic protein selection in simulated in vivo conditions,0,G01N
11866794,2024-01-09,Cas-ready mouse embryonic stem cells and mice and uses thereof,0,A01K|A61K|C07K|C12N|C12Q
11866503,2024-01-09,Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor,1,A61K|A61P|C07K
11866502,2024-01-09,Anti-FGFR2 antibodies and methods of use thereof,0,A61K|A61P|C07K
11865134,2024-01-09,Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors,0,A61K|A61P|C12N|C12Q
11850535,2023-12-26,Methods for quantitating individual antibodies from a mixture,0,A61K|A61P|B01D|C07K|G01N
11845989,2023-12-19,Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors,0,A61K|A61P|C07K|C12N|C12Q
11845963,2023-12-19,HSD17B13 variants and uses thereof,1,A61K|A61P|C12N|C12Q|C12Y|G01N
11845957,2023-12-19,Models of tauopathy,2,A01K|A61K|C12N
11845931,2023-12-19,CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation,4,A61K|C12N|G01N|G16B
11845930,2023-12-19,Methods and systems for CRISPR selection,4,C12N|C12Q|G01N|G16B
11845800,2023-12-19,Methods for treating or preventing asthma by administering an IL-4R antagonist,1,A61K|A61P|C07K|C12Q|G01N
11844765,2023-12-19,Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein,0,A61K|A61P
11835528,2023-12-05,System and method of analysis of a protein using liquid chromatography-mass spectrometry,1,G01N|H01J
11835527,2023-12-05,Deglycosylation methods for electrophoresis of glycosylated proteins,0,C07K|G01N
11834500,2023-12-05,"Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof",1,A61K|A61P|C07K
11834485,2023-12-05,IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof,0,A61K|A61P|C07K
11826386,2023-11-28,Compositions and methods for treating cancer,1,A61K|A61P|C07K|C12N
11825819,2023-11-28,Crnn loss of function rodent model,0,A01K|A61K|C07K
11821001,2023-11-21,Cell culture medium for eukaryotic cells,0,C07K|C12N
11820997,2023-11-21,Methods and compositions for the targeted modification of a genome,0,A01K|C12N
11820982,2023-11-21,Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors,0,A61K|C12N|C12Q
11820826,2023-11-21,Anti-NPR1 antibodies and uses thereof,1,A61K|A61P|C07K
11820815,2023-11-21,Human antibodies to human delta like ligand 4,0,A61K|A61P|C07K
11814428,2023-11-14,Anti-PTCRA antibody-drug conjugates and uses thereof,0,A61K|A61P|C07K
11808766,2023-11-07,Method for generating high affinity antibodies,0,C07K|C12N|G01N
11807665,2023-11-07,Detection and quantification of glycosylated peptides,0,B01D|C07K|G01N
11806398,2023-11-07,Citrate buffered VEGF antagonist formulations,1,A61K|A61P|C07K|Y02A
11788102,2023-10-17,CHO integration sites and uses thereof,0,C12N
11787867,2023-10-17,Anti-GITR antibodies and uses thereof,1,A61K|A61P|C07K
11786606,2023-10-17,Site-specific quantitation of drug conjugations,0,A61K|C12Q|G01N
11786603,2023-10-17,Optimized transglutaminase site-specific antibody conjugation,0,A61K|A61P|C07K
11782023,2023-10-10,Ce-western applications for antibody development,0,C07K|G01N
11781131,2023-10-10,CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation,4,C12N|G01N
11780907,2023-10-10,Human antibodies to influenza hemagglutinin,0,A61K|A61P|C07K
11779633,2023-10-10,Glucagon-like peptide 1 receptor agonists and uses thereof,0,A61K|A61P|C07K|C12N
11778995,2023-10-10,Genetically modified non-human animals and methods of use thereof,0,A01K|A61K|C07K|C12N
11773393,2023-10-03,Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors,0,A61K|A61P|C12N|C12Q
11773156,2023-10-03,Anti-hemagglutinin antibodies and methods of use thereof,0,A61K|A61P|C07K
11771762,2023-10-03,Anti-ErbB3 antibodies and uses thereof,0,A61K|A61P|C07K|C12N
11771743,2023-10-03,Methods for preventing or treating allergy by administering an IL-4R antagonist,1,A61K|A61P|C07K|G01N
11769597,2023-09-26,Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF,0,A61P|C12Q|G16B|G16H
11767526,2023-09-26,Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors,0,A61K|A61P|C07K|C12N|C12Q
11767358,2023-09-26,Human antibodies to Bet v 1 and methods of use thereof,1,A61K|A61P|C07K
11766032,2023-09-26,Genetically modified non-human animals expressing human EPO,0,A01K|A61K|C07K|C12N|C12Q|C12Y|G01N|Y02A
11760775,2023-09-19,Steroids and protein-conjugates thereof,3,A61K|A61P|C07J
11759476,2023-09-19,Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors,0,A61K|A61P|C12Q
11754569,2023-09-12,Methods for characterizing protein complexes,0,G01N
11753628,2023-09-12,HSD17B13 variants and uses thereof,1,A61K|A61P|C12N|C12Q|C12Y|G01N
11753459,2023-09-12,Anti-VEGF protein compositions and methods for producing the same,3,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11752214,2023-09-12,Protein-antiviral compound conjugates,0,A61K
11752197,2023-09-12,Macrophage stimulating 1 receptor (MST1R) variants and uses thereof,0,A61K|A61P|C07K|C12Q|C12Y|G01N
11747340,2023-09-05,Systems and methods for identifying HLA-associated tumor peptides,1,C07K|C40B|G01N
11740246,2023-08-29,Dual-column LC-MS system and methods of use thereof,0,B01D|C07K|G01N
11737435,2023-08-29,Non-human animals comprising a humanized coagulation factor 12 locus,1,A01K|C07K|C12N|C12Q
11732030,2023-08-22,Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments,1,A61K|A61P|C07K|Y02A
11732025,2023-08-22,Anti-VEGF protein compositions and methods for producing the same,7,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11732024,2023-08-22,VEGF antagonist formulations suitable for intravitreal administration,2,A61K|A61M|A61P|C07K
11730794,2023-08-22,Use of a VEGF antagonist to treat angiogenic eye disorders,6,A61K|A61P|C07K
11730793,2023-08-22,Sustained release formulations using non-aqueous emulsions,0,A61K
11730150,2023-08-22,Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy,0,A01K|A61K|C07K
11726096,2023-08-15,Fast protein sequencing,0,C07K|C12Y|G01N|G16B
11725034,2023-08-15,IL2 agonists and methods of use thereof,3,A61K|A61P|C07K|C12N
11717586,2023-08-08,Compositions and methods for reducing bioburden in chromatography,0,A61L|B01D|G01N|G06V|G08G
11714092,2023-08-01,Method and system of identifying and quantifying a protein,0,G01N
11713922,2023-08-01,Target residual moisture content for lyophilized drug product,1,A61K|F26B
11713461,2023-08-01,Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors,0,A61P|C07K|C12N|C12Q
11708416,2023-07-25,Methods of treating severe insulin resistance by interfering with glucagon receptor signaling,0,A61K|A61P|C07K
11708415,2023-07-25,Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1,0,A61K|A61P|C07K|C12Q
11708407,2023-07-25,Antigen binding molecule formats,1,A61K|A61P|C07K
11707506,2023-07-25,Use of a VEGF antagonist to treat angiogenic eye disorders,4,A61K|A61P|C07K
11702700,2023-07-18,Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation,2,C12Q
11701427,2023-07-18,Diels-alder conjugation methods,0,A61K|A61P
11697828,2023-07-11,Methods and compositions for targeted genetic modification using paired guide RNAs,1,A01K|C12N|C12Q
11696572,2023-07-11,Non-human animals comprising a humanized ASGR1 locus,0,A01K|A61K|C07K|C12N
11693010,2023-07-04,Method of characterization of visible and/or sub-visible particles in biologics,1,C07K|G01N|H01J
11692032,2023-07-04,Anti-LAG3 antibodies and uses thereof,0,A61K|A61P|C07K
11690362,2023-07-04,Nuclease-mediated repeat expansion,0,A01K|C07K|C12N
11684050,2023-06-27,Non-human animals having a humanized programmed cell death 1 gene,0,A01K|A61K|A61P|C07K|C12Q|G01N
11680930,2023-06-20,Methods and systems for chromatography data analysis,0,G01N
11674968,2023-06-13,Methods for identifying free thiols in proteins,1,A61K|G01N
11674177,2023-06-13,Kelch domain containing 7B (KLHDC7B) variants and uses thereof,0,A61K|C12Q|G01N
11673967,2023-06-13,Stabilized formulations containing anti-PCSK9 antibodies,0,A61K|A61M|C07K
11673930,2023-06-13,IL10 agonists and methods of use thereof,0,A61K|A61P|C07K
11667701,2023-06-06,Anti-PfRH5 antibodies and antigen-binding fragments thereof,1,A61K|A61P|C07K|Y02A
11666658,2023-06-06,Rifamycin analogs and antibody-drug conjugates thereof,0,A61K|A61P|C07D|C07K|Y02A
11666040,2023-06-06,Humanized non-human animals with restricted immunoglobulin heavy chain loci,0,A01K|C07K|C12P
11655291,2023-05-23,Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A,0,A61K|A61P|C07K
11655286,2023-05-23,"Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof",0,A61K|A61P|C07K
11649273,2023-05-16,Anti-VEGF protein compositions and methods for producing the same,2,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11642390,2023-05-09,Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody,0,A61K|A61P|C07K
11640848,2023-05-02,Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden,1,A61P|C12Q|G16B|Y02A
11639939,2023-05-02,Tandem mass tag multiplexed quantitation of post-translational modifications of proteins,1,G01N
11634480,2023-04-25,Human antibodies to GREM1,0,A61K|A61N|A61P|C07K
11633501,2023-04-25,"Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof",0,A61K|A61P|C07K
11630092,2023-04-18,Online chromatography and electrospray ionization mass spectrometer,3,B01D|C07K|G01N|H01J
11629195,2023-04-18,Anti-IL2 receptor gamma antigen-binding proteins,0,A61K|A61P|C07K|C12N
11622547,2023-04-11,Genetically modified mouse that expresses human albumin,1,A01K|A61K|C07K|C12N
11617357,2023-04-04,Humanized light chain mice,0,A01K|C07K|C12N
11612151,2023-03-28,Humanized light chain mice,0,A01K|C07K|C12N
11608381,2023-03-21,Methods of treatment using a leptin receptor agonist antibody,2,A61K|A61P|C07K
11608380,2023-03-21,Anti-EGFRvIII antibodies and uses thereof,0,A61K|A61P|C07K
11603413,2023-03-14,Anti-TMPRSS2 antibodies and antigen-binding fragments,0,A61K|A61P|C07K|C12N
11603408,2023-03-14,Methods for treating skin infection by administering an IL-4R antagonist,0,A61K|A61P|C07K
11603407,2023-03-14,Stable antibody formulation,0,A61K|C07K
11598756,2023-03-07,Platform for native liquid chromatography-mass spectrometry,0,G01N|H01J
11596690,2023-03-07,Stabilized formulations containing anti-IL-33 antibodies,0,A61K|A61M|C07K
11596635,2023-03-07,"Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses",0,A61K|A61P|C07B|C07D
11594302,2023-02-28,High resolution allele identification,0,A61P|C12Q|G16B
11592449,2023-02-28,Use of LC-MS/MS to quantitate protein biomarkers,1,C12Q|G01N|G16B|G16H
11590223,2023-02-28,Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies,0,A61K|A61P|C07K
11589562,2023-02-28,Mouse model of DITRA disease and uses thereof,0,A01K|C07K|C12N
11584966,2023-02-21,Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof,1,A61K|A61P|C12N|C12Q
11579150,2023-02-14,Methods for characterizing disulfide bonds,1,A61K|G01N
11578135,2023-02-14,Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof,7,A61K|A61P|C07K
11578127,2023-02-14,"Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof",0,A61K|A61P|C07K
11576984,2023-02-14,Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using,0,A01K|A61K
11576356,2023-02-14,Genetically modified non-human animals and methods of use thereof,0,A01K|A61K|A61P|C07K
11571636,2023-02-07,Methods for quantitating individual antibodies from a mixture,0,A61K|A61P|B01D|C07K|G01N
11571482,2023-02-07,Human antibodies to S. aureus Hemolysin A toxin,0,A61K|A61P|C07K
11568957,2023-01-31,Methods and systems for copy number variant detection,0,C12Q|G16B
11560550,2023-01-24,Fucosylation-deficient cells,0,C07K|C12N|C12P|C12Y|Y02P
11559576,2023-01-24,Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof,1,A61K|A61P|C07K
11559564,2023-01-24,Use of a VEGF antagonist to treat angiogenic eye disorders,4,A61K|A61P|C07K
11559489,2023-01-24,Tuning of release kinetics in hydrogels,1,A61K|C07K
11559050,2023-01-24,Humanized non-human animals with restricted immunoglobulin heavy chain loci,1,A01K|C07K|C12P
11555176,2023-01-17,Cell culture medium for eukaryotic cells,0,C07K|C12N
11549154,2023-01-10,Compositions and methods for detecting a biological contaminant,1,C12Q
11548947,2023-01-10,Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof,0,A61K|A61P|C07K
11548932,2023-01-10,Anti-VEGF protein compositions and methods for producing the same,5,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11547101,2023-01-10,Non-human animals having a disruption in a C9ORF72 locus,0,A01K|A61K|A61P|C12N
11547100,2023-01-10,Method for screening gene expression in lincRNA-deficient mice or rats,0,A01K|A61D|C12Q
11542326,2023-01-03,Anti-IL-25 antibodies and uses thereof,0,A61K|A61P|C07K
11542317,2023-01-03,Anti-VEGF protein compositions and methods for producing the same,7,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11536725,2022-12-27,Quantitation and identification of dimers in co-formulations,3,G01N
11535675,2022-12-27,Antigen-binding proteins that antagonize leptin receptor,2,A61K|A61P|C07K
11535663,2022-12-27,Methods for producing aflibercept in chemically defined media having reduced aflibercept variants,3,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11530277,2022-12-20,Compositions and methods for making antibodies based on use of an expression-enhancing locus,0,C07K|C12N|C12Q
11530255,2022-12-20,Human antibodies to Ebola virus glycoprotein,1,A61K|A61P|C07K
11528895,2022-12-20,Genetically modified T cell receptor mice,0,A01K|C07K|C12N
11525833,2022-12-13,Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis,1,B01D|G01N|H01J
11525823,2022-12-13,System and method for characterizing protein dimerization,1,C07K|C12N|G01N
11525629,2022-12-13,Target residual moisture content for lyophilized drug product,2,A61K|F26B
11525001,2022-12-13,Anti-CD8 antibodies and uses thereof,1,A61K|C07K|G01N
11519020,2022-12-06,Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF,0,A61K|A61P|C07K|C12Q|G16B|G16H
11519004,2022-12-06,Transcription modulation in animals using CRISPR/Cas systems,0,A01K|C12N
11518807,2022-12-06,Heavy chain constant regions with reduced binding to Fc gamma receptors,0,C07K
11518804,2022-12-06,Method of treating osteoarthritis with an antibody to NGF,0,A61K|A61P|C07K
11512309,2022-11-29,Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors,0,A61K|A61P|C07K|C12N|C12Q
11512144,2022-11-29,Compositions and methods for making antibodies based on use of an expression-enhancing loci,0,C07K|C12N
11511001,2022-11-29,Radiolabeled anti-LAG3 antibodies for immuno-PET imaging,0,A61K|A61P|C07C|C07K
11505600,2022-11-22,Methods of treating skin cancer by administering a PD-1 inhibitor,0,A61K|A61N|A61P|C07K
11505594,2022-11-22,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11505593,2022-11-22,Anti-VEGF protein compositions and methods for producing the same,8,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11504426,2022-11-22,Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist,0,A61K|A61P|C07K
11504390,2022-11-22,Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors,0,A61K|A61P|C07K|C12N|C12Q
11503813,2022-11-22,Humanized IL-15 animals,0,A01K|C07K|C12N
11503812,2022-11-22,Non-human animals having humanized Fc-gamma receptors,0,A01K|C07K|Y02A
11499951,2022-11-15,Systems and methods for failure mode detection in process chromatography,0,B01D|C07K|G01N
11499164,2022-11-15,Methods for scarless introduction of targeted modifications into targeting vectors,0,C12N
11498970,2022-11-15,Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels,0,A61K|A61P|C07K|C12N
11498969,2022-11-15,Compositions and methods for treating juvenile idiopathic arthritis,1,A61K|A61P|C07K|Y02A
11492392,2022-11-08,Polynucleotides encoding anti-C5 antibodies,0,A61K|A61P|C07K
11491237,2022-11-08,Cyclodextrin protein drug conjugates,4,A61K|A61P|C07J
11491222,2022-11-08,Method of treating lower back pain,0,A61K|A61P|C07K
11486864,2022-11-01,Method and system of identifying and quantifying antibody fragmentation,1,G01N
11485958,2022-11-01,HSD17B13 variants and uses thereof,1,A61K|A61P|C12N|C12Q|C12Y|G01N
11485793,2022-11-01,"Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof",0,A61K|A61P|C07K|G01N
11485788,2022-11-01,Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor,0,A61K|A61P|C07K
11485770,2022-11-01,Anti-VEGF protein compositions and methods for producing the same,4,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11479802,2022-10-25,Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family,0,C12N|C12Q|C12Y|G01N
11479602,2022-10-25,Methods of treating C5-associated diseases comprising administering anti-C5 antibodies,0,A61K|A61P|C07K
11472870,2022-10-18,Pharmaceutical composition for safe and effective treatment of knee and/or hip pain,0,A61K|A61P|C07K
11472861,2022-10-18,Methods for producing aflibercept in chemically defined media having reduced aflibercept variants,3,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11470828,2022-10-18,Rodent model of mood disorders,0,A01K|C07K|C12N
11464830,2022-10-11,Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein,0,A61K|A61P
11464217,2022-10-11,Rodents having genetically modified sodium channels and methods of use thereof,0,A01K|C07K|C12N
11460452,2022-10-04,Devices and systems for chromatography column bed support management and related methods,0,B01D|G01N
11459374,2022-10-04,Anti-VEGF protein compositions and methods for producing the same,9,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11459373,2022-10-04,Anti-VEGF protein compositions and methods for producing the same,5,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11453721,2022-09-27,Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof,0,A61K|A61P|C07K
11453714,2022-09-27,Human antibodies to influenza hemagglutinin,0,A61K|A61P|C07K
11448651,2022-09-20,Modifying binding molecules to minimize pre-exisiting interactions,0,C07K|G01N
11446389,2022-09-20,"Maytansinoid derivatives, conjugates thereof, and methods of use",0,A61K|A61P|C07D|C07K
11440950,2022-09-13,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11439683,2022-09-13,Anti-angiogenic therapy of metastatic colorectal cancer,0,A61K|A61P|G01N
11435359,2022-09-06,Dual-column LC-MS system and methods of use thereof,0,B01D|C07K|G01N
11434300,2022-09-06,Methods and antibody compositions for tumor treatment,0,A61K|A61P|C07K
11428695,2022-08-30,Concentration-dependent self-interaction assay,0,G01N
11421036,2022-08-23,Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R),1,A61K|A61P|C07K
11419319,2022-08-23,Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation,1,A01K|C12N
11419318,2022-08-23,Genetically modified rat comprising a humanized TRKB locus,1,A01K|A61K|C07K|C12N|C12Y
11414494,2022-08-16,Anti-GITR antibodies and uses thereof,2,A61K|A61P|C07K
11407822,2022-08-09,Treatment of fibrodysplasia ossificans progressiva,0,A61K|A61P|C07K
11407813,2022-08-09,Anti-VEGF protein compositions and methods for producing the same,2,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11396544,2022-07-26,Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof,4,A61K|A61P|C07K|C12N
11390663,2022-07-19,Metabolically optimized cell culture,0,C07H|C07K|C12N|C12P|C12Q
11385239,2022-07-12,Method and system of identifying and quantifying a protein,1,G01N
11384153,2022-07-12,Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof,4,A61K|A61P|C07K
11378571,2022-07-05,Methods for evaluating suitability of a biochemical filter,0,B01D|C12M|G01N
11377502,2022-07-05,Anti-MSR1 antibodies and methods of use thereof,1,A61K|A61P|C07K
11371971,2022-06-28,High confidence compound identification by liquid chromatography-mass spectrometry,2,G01N|H01J
11370843,2022-06-28,High affinity antibodies to human IL-6 receptor,0,A61K|A61P|C07K
11369896,2022-06-28,Methods for quantitating individual antibodies from a mixture,0,A61K|A61P|B01D|C07K|G01N
11369707,2022-06-28,Compositions and methods for reducing bioburden in chromatography,0,A61L|B01D|G01N|G06V|G08G
11366123,2022-06-21,Glucuronylation as a new acidic post-translational modification on therapeutic monoclonal antibodies,0,C07K|C12Y|G01N
11365265,2022-06-21,Anti-C5 antibody combinations and uses thereof,0,A61K|A61P|C07K
11359246,2022-06-14,Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors,0,A61K|A61P|C12N|C12Q
11359213,2022-06-14,Methods for analysis of viral capsid protein composition,0,C07K|C12N|G01N
11358984,2022-06-14,Use of Raman spectroscopy in downstream purification,1,C07K|G01N
11357217,2022-06-14,Humanized universal light chain mice,2,A01K|C07K|C12N
11355217,2022-06-07,Quantitation and modeling of quality attributes of therapeutic monoclonal antibodies,0,C07K|C12Q|G01N|G06F|G16B
11352446,2022-06-07,Methods of making multispecific antigen-binding molecules,4,A61K|C07K|C40B
11352417,2022-06-07,Method of treating an allergy with allergen-specific monoclonal antibodies,0,A61K|A61P|C07K
11351256,2022-06-07,Room temperature stable lyophilized protein,4,A61J|A61K|Y02A
11345929,2022-05-31,Methods for analysis of viral capsid protein composition,1,C07K|C12N|G01N
11345715,2022-05-31,"Biologically active molecules, conjugates thereof, and therapeutic uses",0,A61K|A61P|C07D
11333642,2022-05-17,Methods and systems for chromatography data analysis,1,G01N
11332771,2022-05-17,Serum-free cell culture medium,3,C07K|C12N|C12P
11331332,2022-05-17,Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors,0,A61K|C12N|C12Q
11326184,2022-05-10,Methods and compositions for targeted genetic modification through single-step multiple targeting,0,A01K|C12N
11319557,2022-05-03,Multifunctional alleles,0,A01K|C12N
11319375,2022-05-03,Methods and compositions for treating subjects having rheumatoid arthritis,0,A61K|A61P|C07K|G01N
11312936,2022-04-26,Taurine supplemented cell culture medium and methods of use,0,C12N
11306155,2022-04-19,Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody,4,A61K|A61P|C07K
11306148,2022-04-19,Anti-NPR1 antibodies and uses thereof,2,A61K|A61P|C07K
11306135,2022-04-19,Anti-VEGF protein compositions and methods for producing the same,5,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11299532,2022-04-12,Anti-VEGF protein compositions and methods for producing the same,7,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11292847,2022-04-05,Methods for treating atopic dermatitis by administering an IL-4R inhibitor,2,A61K|A61P|C07K
11292842,2022-04-05,Anti-PD-1 antibodies for treatment of lung cancer,1,A61K|A61P|C07K
11291636,2022-04-05,Polymer protein microparticles,1,A61K|A61P
11286460,2022-03-29,Cell culture medium for eukaryotic cells,0,C07K|C12N
11286290,2022-03-29,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11274342,2022-03-15,Systems and methods for sequencing T cell receptors and uses thereof,2,A61K|C07K|C12Q|G16B
11268109,2022-03-08,CHO integration sites and uses thereof,0,C12N
11267893,2022-03-08,Anti-IL36R antibodies,0,A61K|A61P|C07K
11261248,2022-03-01,Restricted immunoglobulin heavy chain mice,0,A01K|A61P|C07K|C12N
11259510,2022-03-01,Humanized T cell mediated immune responses in non-human animals,1,A01K|C07K
11254752,2022-02-22,Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies,0,A61K|A61P|C07K
11253572,2022-02-22,Use of a VEGF antagonist to treat angiogenic eye disorders,10,A61K|A61P|C07K
11249089,2022-02-15,System and method of analysis of a protein using liquid chromatography-mass spectrometry,1,G01N|H01J
11248044,2022-02-15,Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor,2,A61K|A61P|C07K
11241499,2022-02-08,Human serum albumin in formulations,0,A61K
11241498,2022-02-08,Room temperature stable lyophilized protein,1,A61J|A61K|Y02A
11234419,2022-02-01,Mice that make heavy chain antibodies,0,A01K|C07K|C12N
11224208,2022-01-18,Genetically modified major histocompatibility complex mice,0,A01K|C07K|C12N
11224207,2022-01-18,Non-human animals expressing pH-sensitive immunoglobulin sequences,0,A01K|C07K|C12N
11219195,2022-01-11,Genetically modified major histocompatibility complex mice,0,A01K|C07H|C07K|C12N
11214621,2022-01-04,Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist,2,A61B|A61K|A61P|C07K
11208458,2021-12-28,Compositions and methods for internalizing enzymes,19,A61K|A61P|C07K|C12N
11192947,2021-12-07,Histidine engineered light chain antibodies and genetically modified non-human animals for generating same,0,A01K|C07K|C12N
11191844,2021-12-07,Multispecific antigen-binding molecules and uses thereof,4,A61K|A61P|C07K|C12N
11187707,2021-11-30,Method of characterization of visible and/or sub-visible particles in biologics,2,C07K|G01N|H01J
11186848,2021-11-30,Non-human animals expressing humanized C1Q complex,0,A01K|C07K|C12N
11186625,2021-11-30,Anti-VEGF protein compositions and methods for producing the same,7,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11180757,2021-11-23,17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof,1,C12N
11180540,2021-11-23,Anti-VEGF protein compositions and methods for producing the same,2,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11178860,2021-11-23,Humanized C5 animals,0,A01K|A61K|C07K
11174305,2021-11-16,Human antibodies to Fel d1 and methods of use thereof,1,A61K|A61P|C07K|C12N
11174283,2021-11-16,Anti-VEGF protein compositions and methods for producing the same,10,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11168111,2021-11-09,Readily isolated bispecific antibodies with native immunoglobulin format,2,A61K|C07K
11167004,2021-11-09,Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor,1,A61K|A61P|C07K
11155633,2021-10-26,"Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof",4,A61K|A61P|C07K
11155621,2021-10-26,"Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof",2,A61K|A61P|C07K|Y02A
11155598,2021-10-26,GPR156 variants and uses thereof,0,A61P|C07K|C12Q
11142578,2021-10-12,"Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof",0,A61K|A61P|C07K
11130999,2021-09-28,Cas-ready mouse embryonic stem cells and mice and uses thereof,1,A01K|A61K|C07K|C12N|C12Q
11129903,2021-09-28,Multispecific antigen-binding molecules and uses thereof,7,A61K|A61P|C07K|C12N
11117970,2021-09-14,Human antibodies to PD-L1,2,A61K|A61P|C07K
11117955,2021-09-14,Anti-Zika virus antibodies and methods of use,1,A61K|A61P|C07K|Y02A
11116839,2021-09-14,Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9),4,A61K|A61P|C07K
11111504,2021-09-07,Methods for scarless introduction of targeted modifications into targeting vectors,1,C12N
11111314,2021-09-07,Non-human animals that select for light chain variable regions that bind antigen,0,A01K|C07K
11109578,2021-09-07,Humanized IL-4 and IL-4Ra animals,1,A01K|C07K
11104730,2021-08-31,Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors,0,A61K|A61P|C07K
11104729,2021-08-31,Anti-IL-33 antibodies and uses thereof,1,A61K|A61P|C07K
11104715,2021-08-31,Methods for producing aflibercept in chemically defined media having reduced aflibercept variants,4,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11103552,2021-08-31,High concentration VEGF receptor fusion protein containing formulations,2,A61K|A61P|C07K
11102962,2021-08-31,Humanized IL-6 and IL-6 receptor,0,A01K|C07K|C12N
11102961,2021-08-31,Non-human animals having a humanized lymphocyte-activation gene 3,0,A01K|A61K|C07H|C07K|C12N
11098363,2021-08-24,Cornulin (CRNN) variants and uses thereof,0,C07K|C12Q
11098311,2021-08-24,Anti-VEGF protein compositions and methods for producing the same,2,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11098127,2021-08-24,Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies,1,A61J|A61K|A61P|C07K
11098112,2021-08-24,Anti-VEGF protein compositions and methods for producing the same,1,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11085053,2021-08-10,Efficient selectivity of recombinant proteins,0,C07K|C12N|C12P
11084865,2021-08-10,VEGF antagonist formulations suitable for intravitreal administration,13,A61K|A61M|A61P|C07K
11072656,2021-07-27,"Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof",2,A61K|A61P|C07K|Y02A
11071780,2021-07-27,Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab,0,A61K|A61P|C07K
11066474,2021-07-20,Anti-TrkB monoclonal antibodies and methods of use,0,A61K|A61P|C07K
11066458,2021-07-20,VEGF antagonist formulations suitable for intravitreal administration,12,A61K|A61M|A61P|C07K
11064685,2021-07-20,Non-human animal models of retinoschisis,0,A01K|A61P|C07K|C12N|G01N
11059896,2021-07-13,Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies,1,A61K|A61M|A61P|C07K
11054389,2021-07-06,Microchip capillary electrophoresis assays and reagents,2,G01N
11053309,2021-07-06,Methods for treating active eosinophilic esophagitis,10,A61K|A61P|C07K
11053280,2021-07-06,Anti-VEGF protein compositions and methods for producing the same,14,A61K|A61P|C07K|C12N|C12P|C12Y|G01N
11051499,2021-07-06,Genetically modified mice and engraftment,2,A01K|A61K|C07K|C12N|Y02A
11051498,2021-07-06,Mouse having an engineered immunoglobulin lambda light chain,0,A01K|C07K|C12N
11047863,2021-06-29,Methods for de novo protein sequencing,1,C07K|G01N|G16B|H01J
11045522,2021-06-29,Glucagon-like peptide 1 receptor agonists and uses thereof,1,A61K|A61P|C07K|C12N
11034768,2021-06-15,Methods for treating or preventing asthma by administering an IL-4R antagonist,12,A61B|A61K|A61P|C07K
11026997,2021-06-08,Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein,0,A61K|A61P
11026408,2021-06-08,Genetically modified non-human animals and methods of use thereof,1,A01K|C07K|C12N
11026407,2021-06-08,Mice expressing a limited immunoglobulin light chain repertoire,1,A01K|C07K|C12N
11021719,2021-06-01,Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo,1,A01K|C12N|C12Y
11020686,2021-06-01,Methods for quantitating individual antibodies from a mixture,0,A61K|A61P|B01D|C07K|G01N
11020495,2021-06-01,Humanized low affinity FCγR mouse cells,1,A01K|A61K|C07K|G01N
11019810,2021-06-01,Non-human animals having a humanized signal-regulatory protein gene,1,A01K|A61K|C07K|C12N|C12Y|G01N
11013220,2021-05-25,Humanized dipeptidyl-peptidase IV (DPP4) animals,0,A01K|A61P|C12N|C12Q|C12Y|G01N
11000020,2021-05-11,Non-human animals having a humanized B-cell activating factor gene,0,A01K|C07K|C12N|G01N
10995150,2021-05-04,Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody,4,A61K|A61P|C07K|Y02A
10995146,2021-05-04,Methods of treating severe insulin resistance by interfering with glucagon receptor signaling,0,A61K|A61P|C07K
10988776,2021-04-27,Methods of modifying genes in eukaryotic cells,0,A01K|A61D|C12N
10988537,2021-04-27,Antibodies comprising chimeric constant domains,2,A61P|C07K|C12N
10986822,2021-04-27,Genetically modified major histocompatibility complex mice,0,A01K|C07H|C07K|C12N
10986820,2021-04-27,Common light chain mouse,0,A01K|C07K|C12N
10980221,2021-04-20,Non-human animals expressing exogenous terminal deoxynucleotidyltransferase,0,A01K|C07K|C12N|C12Y
10976241,2021-04-13,Methods of assessing antibody-drug conjugates,0,B01D|G01J|G01N|G16B|G16C
10975390,2021-04-13,Targeted modification of rat genome,2,A01K|A61D|C07K|C12N
10975139,2021-04-13,Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments,4,A61K|A61P|C07K|Y02A
10973879,2021-04-13,Use of a VEGF antagonist to treat angiogenic eye disorders,4,A61K|A61P
10968278,2021-04-06,Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same,1,A61K|A61P|C07K
10961583,2021-03-30,Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation,5,C12Q
10961500,2021-03-30,Cell culture medium for eukaryotic cells,0,C07K|C12N
10954310,2021-03-23,Mice that make VL binding proteins,0,A01K|C07K|C12N
10954289,2021-03-23,Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments,12,A61K|A61P|C07K|Y02A
10952416,2021-03-23,Method for generating a humanized transgenic mouse comprising a human APRIL gene,0,A01K|C07K|C12N|G01N
10947312,2021-03-16,Human antibodies to GFRα3 and methods of making thereof,0,A61K|A61P|C07K
10947310,2021-03-16,Fusion protein comprising apelin and an anti-APLNR antibody,1,A61K|A61P|C07K
10941213,2021-03-09,Anti-TMPRSS2 antibodies and antigen-binding fragments,0,A61K|A61P|C07K|C12N
10941210,2021-03-09,Anti-PCSK9 antibodies,4,A61K|A61P|C07K|C12N|C12Y|G01N|Y10S
10941208,2021-03-09,Anti-MUC16 antibodies,1,A61K|A61P|C07K|G01N
10940211,2021-03-09,Human antibodies to S. aureus hemolysin A toxin,1,A61K|A61P|C07K
10939673,2021-03-09,Method of using mouse having a humanized cluster of differentiation 47 gene,1,A01K|A61P|C07K|C12N|G01N
10935554,2021-03-02,"Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)",2,A61K|G01N
10934349,2021-03-02,Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody,1,A61K|A61P|C07K
10932455,2021-03-02,Non-human animals expressing humanized CD3 complex,0,A01K|C07K|C12N|G01N|Y02A
10927435,2021-02-23,Compositions for the treatment of rheumatoid arthritis and methods of using same,5,A61K|A61P|B21D|B21J|C07K|C22C|C22F
10927342,2021-02-23,Taurine supplemented cell culture medium and methods of use,15,C12N
10925986,2021-02-23,Compositions and methods for reducing bioburden in chromatography,1,A61L|B01D|G01N|G06V|G08G
10925971,2021-02-23,Methods of treating PRLR positive breast cancer,1,A61K|A61P|C07K
10908166,2021-02-02,Dual-column LC-MS system and methods of use thereof,1,B01D|C07K|G01N
10905784,2021-02-02,Radiolabeled anti-LAG3 antibodies for immuno-PET imaging,3,A61K|A61P|C07C|C07K
10905109,2021-02-02,ADAM6 mice,5,A01K|B60H|C07K|C12N
10905108,2021-02-02,ADAM6 mice,3,A01K|B60H|C07K|C12N
